Grufity logoGrufity logo

VXRT

1.30USD+0.13(+11.11%)Delayed

Vaxart Inc

Market Summary

USD1.30+0.13Delayed
11.11%

VXRT Stock Price

RSI Chart

Valuation

Market Cap

218.9M

Price/Earnings

-2.36

Price/Sales

609.63

Price/Cashflow

-2.7

MarketCap/EBT

-2.36

Price/Sales

Profitability

Operating Margin

-3767.71%

EBT Margin

-25850.70%

Return on Equity

-64.91%

Return on Assets

-51.19%

Fundamentals

Revenue

Revenue Y/Y

-100%

Revenue Q/Q

-100%

Earnings

Earnings (TTM)

-104.6M

Earnings Y/Y

-66.69%

Earnings Q/Q

0.41%

Price Action

52 Week Range

7.61
(Low)(High)

Last 7 days

1.6%

Last 30 days

-15.6%

Last 90 days

-54.4%

Trailing 12 Months

-80.6%

Financial Health

Current Ratio

8.65

Debt/Equity

0.09

Debt/Cashflow

-3.37

Investor Care

Shares Dilution (1Y)

4.58%

Peers (Alternatives to Vaxart)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
146.5B
26.3B
6.86% 46.41%
22.27
5.55
2.18% 21.86%
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
41.3B
10.4B
7.38% 30.80%
14.4
3.98
-6.64% 85.32%
11.1B
1.4B
3.89% 57.25%
905.99
8.52
29.86% -86.92%
MID-CAP
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
3.4B
-
7.39% -35.47%
-14.65
59.51
215916.67% 21.41%
2.1B
68.3M
4.34% -60.25%
-8.33
30.98
42.18% -19.70%
2.0B
432.8M
45.87% -20.63%
29.99
4.9
1042.97% 128.67%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
1.6B
69.7M
-4.82% -76.34%
-3.15
20.84
745.14% -7.72%
891.0M
3.2M
5.78% -29.88%
-6.7
275.59
11.14% -46.59%
692.0M
114.2M
-14.32% -56.80%
-4.02
6.06
-17.11% -27.41%
458.1M
-
-17.48% -90.68%
-13.56
44.06
522.71% -129.91%
218.9M
-
-15.58% -80.57%
-2.36
609.63
-71.03% -64.56%

Financials for Vaxart

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-100.0%null3594718921,174
Operating Expenses12.5%107,82395,84882,48873,64463,072
  S&GA Expenses7.2%28,69326,77522,60421,89021,262
  R&D Expenses15.2%76,12566,06856,87948,74941,810
Earnings Before Taxes-12.6%-104,535.00-92,804.00-79,475.00-70,363.00-63,445.00
Net Income-12.6%-104,604.00-92,878.00-79,564.00-70,470.00-63,567.00
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-3.4%175181200221241
  Current Assets-12.6%120138154169192
    Cash Equivalents-44.5%5191123144167
  Net PPE31.5%129875
  Goodwill0%5555-
Liabilities38.2%5338343436
  Current Liabilities36.5%2216111113
Shareholder's Equity-14.5%122143166188205
  Retained Earnings-10.7%-303.19-273.88-244.45-219.35-198.59
  Additional Paid-In Capital2.1%426417411407404
Accumulated Depreciation23.0%32211
Shares Outstanding1.5%128126126126125
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-0.4%-81.44-81.09-68.35-59.83-54.78
  Share Based Compensation13.4%13121196
Cashflow From Investing-150.4%-44.39-17.73-24.81-49.10-41.82
Cashflow From Financing-62.6%92559126130

Risks

What is the probability of a big loss on VXRT?

100%


Probability that Vaxart stock will be more than 20% underwater in next one year

100%


Probability that Vaxart stock will be more than 30% underwater in next one year.

98.8%


Probability that Vaxart stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VXRT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Vaxart was unfortunately bought at previous high price.

Returns

Cumulative Returns on VXRT

-28.2%


5-Year Cumulative Returns

59.7%


3-Year Cumulative Returns

What are the long-term rolling returns for VXRT?

FIve years rolling returns for Vaxart.

Which funds bought or sold VXRT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
IHT Wealth Management, LLC
-
-
-320,000
589,000
0.04%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
-213,000
344,000
-%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
-1,000
1,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-2,000
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
1,126
595,605
685,355
-%
2022-11-15
JANE STREET GROUP, LLC
ADDED
21.87
-124,000
393,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
ADDED
22.52
-88,000
282,000
-%
2022-11-15
Balyasny Asset Management LLC
NEW
-
116,000
116,000
-%
2022-11-15
HARBOUR INVESTMENTS, INC.
UNCHANGED
-
-
5,000
-%
2022-11-15
STATE STREET CORP
ADDED
11.03
-13,679,000
30,673,000
-%

1–10 of 39

Latest Funds Activity

Are funds buying VXRT calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own VXRT

Vaxart News

Marketscreener.com

Vaxart to Start Clinical Trial of Oral Norovirus Vaccine in Breastfeeding Mothers.3 days ago

The Motley Fool

VXRT Fair Value

Recent SEC filings of Vaxart

View All Filings
Date Filed Form Type Document
Nov 09, 2022
10-Q
Quarterly Report
Nov 08, 2022
8-K
Current Report
Oct 24, 2022
S-8
Employee Benefits Plan
Oct 07, 2022
4
Insider Trading
Sep 01, 2022
8-K
Current Report
Aug 26, 2022
4
Insider Trading
Aug 25, 2022
8-K
Current Report
Aug 25, 2022
4
Insider Trading
Aug 25, 2022
3
Insider Trading

Latest Insider Trading transactions for VXRT

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-25
HERON ELAINE J
ACQUIRED
-
-
14,750
-
2022-08-24
Yedid Robert A.
GIFTED
-
-
-26,240
-
2022-08-19
Yedid Robert A.
ACQUIRED
24,774.4
0.944146
26,240
-
2022-08-04
Davis Todd C
ACQUIRED
-
-
7,375
-
2022-08-04
Yedid Robert A.
ACQUIRED
-
-
7,375
-
2022-08-04
Cherrington Julie M
ACQUIRED
-
-
6,217
-
2022-08-04
Wheadon David E.
ACQUIRED
-
-
7,375
-
2022-08-04
Finney Michael J.
ACQUIRED
-
-
7,375
-
2022-08-04
Watson W. Mark
ACQUIRED
-
-
14,750
-
2022-06-22
Ahmad Fuad
BOUGHT
16,100
3.22
5,000
Interim CFO

1–10 of 50

Andrei Floroiu
110
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

VXRT Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue from Contract with Customer, Including Assessed Tax$ 0$ 200$ 85$ 818
Operating expenses:    
Research and development22,46612,40960,59533,219
General and administrative6,9605,04222,93916,136
Total operating expenses29,42617,45183,53449,355
Operating loss(29,426)(17,251)(83,449)(48,537)
Other income (expense):    
Interest income, net4582665058
Non-cash interest expense related to sale of future royalties(325)(337)(988)(1,137)
Foreign exchange loss, net00(2)(1)
Loss before income taxes(29,293)(17,562)(83,789)(49,617)
Provision for income taxes16215189
Net loss$ (29,309)$ (17,583)$ (83,840)$ (49,706)
Net loss per share - basic and diluted (in dollars per share)$ (0.23)$ (0.14)$ (0.66)$ (0.41)
Shares used to compute net loss per share - basic and diluted (in shares)126,889,718123,984,141126,374,424120,110,780
Comprehensive loss:    
Net loss$ (29,309)$ (17,583)$ (83,840)$ (49,706)
Unrealized (loss) gain on available-for-sale investments, net of tax(109)6(444)(3)
Comprehensive loss(29,418)(17,577)(84,284)(49,709)
Customer Service Contracts [Member]    
Revenue from Contract with Customer, Including Assessed Tax00013
Non Cash Royalty Revenue [Member]    
Revenue from Contract with Customer, Including Assessed Tax$ 0$ 200$ 85$ 805

VXRT Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 50,768$ 143,745
Short-term investments63,99922,742
Accounts receivable071
Prepaid expenses and other current assets5,6132,609
Total current assets120,380169,167
Long-term investments016,210
Property and equipment, net12,2806,601
Right-of-use assets, net26,60713,168
Intangible assets, net9,61110,624
Goodwill4,5084,508
Other long-term assets1,923890
Total assets175,309221,168
Current liabilities:  
Accounts payable7,9163,872
Current portion of operating lease liability2,1491,011
Current portion of liability related to sale of future royalties1,331836
Other accrued liabilities10,3445,064
Total current liabilities21,74010,783
Operating lease liability, net of current portion20,01911,997
Liability related to sale of future royalties, net of current portion11,02710,686
Other long-term liabilities216171
Total liabilities53,00233,637
Commitments and contingencies (Note 8)
Stockholders’ equity:  
Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of September 30, 2022 and December 31, 202100
Common stock: $0.0001 par value; 250,000,000 shares authorized; 128,331,408 and 125,594,393 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively1313
Additional paid-in capital426,003406,943
Accumulated deficit(303,191)(219,351)
Accumulated other comprehensive loss(518)(74)
Total stockholders’ equity122,307187,531
Total liabilities and stockholders’ equity$ 175,309$ 221,168